Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     
News

Australian company releases positive MIGS study

30/10/2018By Myles Hume
Share
More than one in three glaucoma patients who have undergone Ellex Medical Lasers’ ab-interno canaloplasty (ABiC) procedure are medication-free after a year, research has revealed.

Other patients of the minimally invasive glaucoma surgery (MIGS) procedure experienced a 60% reduction in medication use, while intraocular pressure (IOP) dropped 32.3% on average.

A consecutive case series led by Texan surgeon Dr Mark Gallardo – a glaucoma specialist and pioneer of ABiC – has shown the clinical safety and efficacy of the procedure during a 12-month follow-up period, performed with the iTrack surgical system.

Unlike typical MIGS procedures that involve a permanent implant or device, the Australian-based company’s ABiC procedure acts to restore the eye’s natural outflow system. Ellex claims it is the only MIGS procedure that addresses the three aspects of potential outflow resistance to date.


“ABiC is safe and effective in lowering IOP and medication dependency in eyes with uncontrolled primary open-angle glaucoma.”
Mark Gallardo, study lead

The study compared the effectiveness of ABiC when performed in a standalone procedure, or in conjunction with a cataract extraction. It based the results on the reduction of intraocular pressure (IOP) and medication dependence.

Of the 75 eyes from 68 patients with uncontrolled primary open-angle glaucoma (POAG) assessed in the study, 41 received a standalone procedure while 34 had a combination of ABiC and phacoemulsification.

In the standalone patients, IOP had reduced 32.8% after one year, and they experienced a 51.1% reduction in medication use. Almost 31% of eyes treated were medication-free.

In the combined cataract procedure, IOP reduced 31.7%, while medication use fell 71.1%. After 12 months, exactly half were medication-free.

The study also found, on average, 84.9% of eyes experienced a reduction in IOP of more than 20%. Overall, there was a significant reduction in mean IOP (32.3%) and medications (60%) from baseline at 12 months follow-up.

The data demonstrated the device was effective in uncontrolled POAG with or without cataract surgery, the study authors said.

“ABiC is safe and effective in lowering IOP and medication dependency in eyes with uncontrolled POAG,” the report concluded.

“Given the minimally invasive, non-destructive nature of the procedure, further angle surgery can be performed if necessary including LTP, goniotomy, trabeculotomy, or trabecular micro-bypass. And as other MIGS, ABiC has a limited postoperative recovery compared to other more invasive filtering procedures, lending itself to being adjunctively added to cataract extraction.”

leaderboard-Nova tears
advertisement

The study was recently published in Clinical Ophthalmology.

largeleaderboard
advertisement





rectangle
advertisement
Editor's Suggestion
Hot Stories

OR
 

Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!